Liquid alternative to desmopressin tablets allows for more precise dosing ...

The FDA has approved an oral liquid therapy for the treatment of central diabetes insipidus in people of all ages, according to a press release. Desmopressin acetate (Desmoda, Eton Pharmaceuticals) is ...

Diabetes insipidus is a rare condition that leads to excessive urination. This can lead to severe dehydration and high sodium levels — and these can mean serious complications. Share on Pinterest ...

Mechanistically, thirst starts with the excitation of osmoregulatory cells in a brain structure called the lamina terminalis, which is located in the anterior wall of the third ventricle. The lamina ...

Transient diabetes insipidus almost always begins within 24-48 h of surgery, and usually abates within several days. Both transient diabetes insipidus and the first phase of the triphasic pattern are ...

Aquaporin-2 (AQP2) is a critical water channel in the renal collecting ducts that governs water reabsorption and urine concentration. Dysregulation of AQP2, through genetic mutations or acquired ...

Diabetes mellitus—known to many as type 1 and type 2 diabetes—gets all the attention with its rising global prevalence and connection to lifestyle and autoimmunity. Meanwhile, its lesser-known ...

Eton Pharmaceuticals submitted an NDA for ET-600, an oral solution for central diabetes insipidus, targeting a Q1 2026 launch. Eton Pharmaceuticals announced the submission of a New Drug Application ...

From the George F. Baker Clinic, Elliott P. Joslin, M.D., Medical Director, at the New England Deaconess Hospital, Boston. Select the format you want to export the citation of this publication.

Clinicians now have an FDA-approved liquid desmopressin option for central diabetes insipidus, designed for dosing consistency across the age spectrum.

FDA authorized desmopressin acetate oral solution (Desmoda) for CDI/AVP-D across all ages, representing the first FDA-approved oral liquid desmopressin formulation in the United States.